T he heart possesses intrinsic mechanisms to provide protection against injurious stimuli such as ischemia and reperfusion (reviewed elsewhere 1, 2 ). These include an enhanced expression of the inducible isoform of cyclooxygenase (COX-2), 3 which increases the cardiocoronary formation of vasodilatory prostaglandins. 2 Prostaglandins mediate cardioprotection in various in vitro and animal models of ischemia-and reperfusionassociated myocardial injury. 4 -6 Earlier work from our 7 and other laboratories 8 suggested that the antiischemic action of prostaglandins is mediated, at least in part, by receptors specific for E-type prostaglandins (EP receptors).
Prostaglandins exert their effects via G-protein-coupled receptors. Therefore, prostaglandin-mediated cardioprotection probably involves one of the EP receptor subtypes, namely EP 1 , EP 2 , EP 3 , and EP 4 . These differ with respect to their signaling pathways. 9 EP 1 couples to G q and increases intracellular Ca 2ϩ . EP 2 and EP 4 couple to G s and stimulate adenylate cyclase with subsequent increase in intracellular cAMP. EP 3 receptors couple to G i and inhibit the increase of cAMP. It has recently been shown that EP 3 receptor agonists protect the reperfused myocardium from ischemic injury, suggesting a particular role of this subtype for cardioprotection. 7, 10, 11 Nevertheless, it is unknown where the EP 3 receptors, which prevent ischemic myocardial injury, are located and what their postreceptor signaling pathway is. EP 3 receptors are expressed by many cell types, including neuronal, vascular, and cardiac tissues. [12] [13] [14] [15] We hypothesized that EP 3 receptors expressed on cardiomyocytes mediate the improvement of myocardial tolerance to ischemia. To test this hypothesis, we used the cardiomyocyte-specific ␣-myosin heavy chain (␣-MHC) promoter to overexpress the EP 3 receptor in mice. 16 The porcine EP 3 receptor was chosen because previous work has demonstrated an E-type prostaglandin-mediated reduction of infarct size in pigs. 7 Isolated hearts from transgenic (tg) and wild-type (wt) mice were characterized with respect to G-protein coupling and the response to global ischemia and reperfusion.
It is shown that EP 3 receptor overexpression on cardiomyocytes considerably reduces ischemic myocardial injury, as indicated by an attenuation of contracture during ischemia and a reduction in the release of intracellular markers of ischemic injury during reperfusion.
Methods
The study was approved by the institutional and governmental Animal Research Committee and was conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Chemicals were from Sigma and Merck if not otherwise indicated.
Generation of EP 3 Receptor-Overexpressing Mice
Mice with cardiac-specific overexpression of the EP 3 receptor were created using standard techniques. 15 Briefly, a linear NotI 7.7-kb DNA fragment that contained the ␣-MHC promoter 16 and the full-length porcine EP 3 receptor cDNA ( Figure 1 ) was microinjected into the pronuclei of fertilized mouse oocytes (C57Bl6/C3H). The transgene was detected in F0 mice by PCR analysis of genomic tail sample DNA using an upstream primer specific for the ␣-MHC promoter (5Ј-ACTGTGGTGCCTCGTTCCAG-3Ј) and a downstream primer specific for the overexpressed EP 3 receptor (5Ј-CATGGCACTGGCGATGAAG-3Ј). Tg animals display a specific 850-bp DNA fragment. Tg founders were bred with C57Bl/6 mice. Heterozygous animals from at least the third generation were used for the study. Wt littermates served as controls.
Receptor Expression (RT-PCR)
Total RNA from different tissues was prepared with Trizol reagent (Gibco). RNA was quantified spectrophotometrically. RT-PCR for tg EP 3 receptor expression was performed with a Qiagen One-Step RT-PCR kit (Qiagen) using the above-mentioned primers specific for the ␣-MHC gene promoter and the downstream primer specific for tg EP 3 receptor. Transgene expression resulted in a specific 560-bp fragment.
Ligand Binding Measurements
Ligand binding was studied as described previously. 14 Briefly, hearts from anesthetized wt and tg mice (nϭ5 to 6 per group) were homogenized in 3 mL of buffer containing (mmol/L) Tris-HCl 50 (pH 7.4), Na-EDTA 5, and EGTA 2 for 3ϫ6 seconds with an Ultraturrax homogenizer. The homogenates were filtered and centrifuged (10 minutes at 220g). The supernatants were sedimented (48 000g, 10 minutes), and the pellets were washed twice (50 mmol/L Tris-HCl, pH 7.4) and stored frozen until use. Thereafter, cardiomyocytes were incubated with Hank's balanced salt solution (1 mg/mL BSA, 10 mmol/L HEPES, pH 7.3) and 1 mmol/L isobutyl methylxanthine for 10 minutes at 37°C. Cells were stimulated with 10 mol/L forskolin, the EP 3 receptor agonist M&B 28.767 (100 nmol/L, 15␣-hydroxy-9 -oxo-16 -phenoxy-17,18,19,20 -tetranorprost-13-transenoic acid) or both for 10 minutes. M&B 28.767 was a gift from Rhône-Poulenc Rorer. The reaction was stopped with ice-cold 96% ethanol; the samples were dried and overlaid with 0.3 mL buffer containing (mmol/L) Tris/HCl 50 (pH 7.5), Na-EDTA 4, and cAMP determined in the supernatant by radioimmunoassay. Protein was measured according to Bradford (Bio-Rad). cAMP formation was expressed as picomoles per milligram protein per 10 minutes. The effect of forskolin on cAMP was also studied after pretreatment of the cells with 2 g/mL pertussis toxin (PTX) for 4 hours.
Protein Kinase C-Dependent Substrate Phosphorylation
Proteins were prepared from mouse hearts and separated by polyacrylamide gel electrophoresis as described earlier. 17 To detect EP 3 receptor-dependent protein kinase C (PKC) activation, a PKC substrate-selective antibody was used as recommended by the manufacturer (Cell Signaling Technology, catalog No. 2261). This antibody specifically identifies PKC-dependent serine phosphorylation. Immunoreactivity was visualized by enhanced chemiluminescence (Roche Diagnostics).
Analysis of Left Ventricular Function In Vivo
Parameters of left ventricular function were determined in vivo with a vertical Bruker DRX 9.4-T wide-bore NMR spectrometer, equipped with an actively shielded 40-mm gradient set (capable of 1-T/m maximum gradient strength) and a 30-mm birdcage resonator. Animals were kept at body temperature (37°C) throughout the measurements.
High-resolution images were acquired by an ECG and respirationtriggered FLASH cine sequence (repetition time, 5 ms; echo time, 2.5 ms; flip angle Ͻ30°; field of view, 30ϫ30 mm 2 ; matrix size, 128ϫ128 zero-filled to 256ϫ256; slice thickness, 1 mm). 18 Six to eight contiguous ventricular short-axis slices were acquired to cover 
Martin et al Cardiac EP 3 Receptor Overexpression 401
the entire heart. The cavity volumes in each slice were obtained by multiplying measured component area by slice thickness, with correction at the base and apex from additional coronal slices. Stroke volume (SV) was determined as the difference of end-diastolic volume (EDV) and end-systolic volume, respectively. Ejection fraction was calculated as SV/EDVϫ100%. Cardiac output was defined as the product of stroke volume and heart rate.
Isolated Heart Perfusion
All mice were pretreated with heparin (1250 IU IP) and anesthetized with urethane (3.2 g/kg IP). After the hearts were excised, the aortas were attached to a 20-gauge needle and perfused at a pressure of 80 mm Hg with modified Krebs-Henseleit buffer containing (mmol/L) NaCl 118, NaHCO 3 Surface electrodes were applied to the right atria, and the hearts were paced at 500 minutes Ϫ1 . All hearts were allowed to equilibrate for 20 minutes. Then, perfusion was stopped for 1 hour (ischemia), and the hearts were reperfused for 45 minutes. A water-filled intraventricular balloon served to measure end-diastolic left ventricular pressure (LVEDP), developed left ventricular pressure (⌬LVP), and maximum change in LVP (dP/dt max , ϪdP/dt max ). Coronary flow was also measured continuously (electromagnetic flowmeter MDL 401, Skalar). Functional data were recorded on a MacLab system (ADInstruments). Creatine kinase (CK) and lactate dehydrogenase (LDH) activities were determined in the coronary effluate using spectrofluorometric assay kits (Cypress Diagnostics).
A separate group of tg and wt hearts (nϭ3 to 5) served to determine the inotropic effect of isoproterenol during normoxic isolated perfusion. Isoproterenol was added to the perfusate at concentrations of 3 to 1000 nmol/L. Additional experiments (nϭ4 per group) were performed in the presence of the ␤ 1 -selective adrenergic antagonist talinolol (AWD Pharma). 19 Talinolol was dissolved in the perfusate at a concentration of 3 mol/L, a concentration sufficient to antagonize the inotropic effect of isoproterenol in the isolated perfused heart preparation (not shown).
Statistical Analysis
Data are given as meanϮSEM from n independent experiments. Concentration-response curves and ligand binding data were analyzed by computerized curve fitting (GraphPad). Differences between groups were examined by 2-tailed t test for paired and unpaired samples as appropriate. Multiple comparisons were performed by ANOVA, followed by Bonferroni's test. Values of PϽ0.05 were considered significant.
Results

Transgene Expression
Three founder mice were obtained that showed EP 3 receptor overexpression under control of the ␣-MHC promoter. In the line selected for this study, transgene expression assessed by RT-PCR was abundant in the heart, very weak in lung and aorta, and negative in all other tissues studied ( Figure 1 ). Ligand binding assays performed with cardiac membranes of wt animals revealed only low EP 3 receptor expression (B max ϭ59Ϯ14 fmol/mg protein). More than 40-fold-higher specific binding was observed in tg littermates (B max ϭ2605Ϯ488 fmol/mg protein; PϽ0.01 versus wt). The binding affinities (K d ) were not significantly different between wt (20Ϯ4 nmol/L) and tg (32Ϯ5 nmol/L) hearts.
MRI Analysis of Left Ventricular Function
MRI revealed that the end-systolic volumes were 56% higher in tg compared with wt hearts, whereas there was no significant difference in the end-diastolic volumes, resulting in a 17% decrease in left ventricular ejection fraction in tg mice. These changes, however, did not impair global myocardial function, because cardiac output was comparable in tg and wt animals ( Table 1) .
Coupling of the EP 3 Receptor to Intracellular Signaling Cascades
The main physiological signal transduction pathway of prostaglandin EP 3 receptors is coupling to G i . To examine transgenic receptor coupling to G i , cAMP formation was studied in cardiomyocytes from tg and wt mice after stimulation with forskolin, a direct activator of adenylate cyclase. Compared with wt, forskolin increased cAMP much less in cardiomyocytes from tg mice, indicating constitutive transgenic receptor coupling to G i (Figure 2) . Consistent with constitutive receptor activity, the forskolin-induced increase in cAMP was not altered by the EP 3 agonist M&B 28.767 in tg cardiomyocytes. Moreover, the receptor expression of wt cardiocytes has probably been too low for inhibition of forskolin-stimulated cAMP by M&B 28.767 (Figure 2) . Preincubation of cardiocytes from tg mice with PTX restored the forskolin-induced cAMP increase in tg cardiomyocytes to values comparable to those of wt, confirming that the overexpressed EP 3 receptor constitutively couples to G i .
Membranes from wt and tg hearts showed considerable immunoreactivity when probed with a PKC substrateselective antibody. However, comparison between wt and tg hearts did not reveal differences in PKC-dependent substrate phosphorylation (Figure 3 ).
Left Ventricular Function of Isolated Perfused Hearts
Baseline myocardial function of wt (nϭ8) and tg hearts (nϭ6) is given in Table 2 . There were no major differences between wt and tg hearts in LVEDP, ⌬LVP, dP/dt max , ϪdP/ dt max , and coronary flow.
Isoproterenol increased ⌬LVP concentration-dependently in wt hearts to a maximum of 168Ϯ10 mm Hg. In tg hearts, the inotropic effect of isoproterenol was attenuated, as shown by a maximum stimulation of ⌬LVP to 122Ϯ9 mm Hg (PϽ0.05 versus wt). The concentrations required for half-maximal stimulation were not significantly different between wt and tg hearts (log EC 50 ϭϪ8.48Ϯ0.18 versus Ϫ8.07Ϯ0.20). Similar results were obtained for dP/dt max (not shown).
When isolated perfused hearts were subjected to global ischemia (60 minutes), ⌬LVP and dP/dt max declined to 0 in both groups and partially recovered at 5 and 45 minutes of reperfusion to Ϸ50% and 75% of the preischemic control value (not shown). There were no significant differences between groups.
However, hearts from wt and tg mice substantially differed in LVEDP. As a result of ischemic ventricular contracture, LVEDP started to rise after 10 minutes in wt hearts and rapidly increased to a maximum of 39.9Ϯ3.6 mm Hg at 20 minutes of ischemia (Figure 4 ). EP 3 overexpression caused an impressive delay of the onset of ischemic contracture. Moreover, LVEDP was significantly lower in tg than in wt hearts (16.9Ϯ6.2 versus 40.5Ϯ3.2 mm Hg at 40 minutes of ischemia; PϽ0.05).
LVEDP of wt hearts declined to 20.3Ϯ5.8 mm Hg within 45 minutes of reperfusion, which significantly exceeded the control value before ischemia (PϽ0.05; Figure 4 ). In contrast, LVEDP returned in tg hearts to 2.8Ϯ1.3 mm Hg at 45 minutes of reperfusion. This was comparable to the preischemic control and significantly less than in the wt hearts (PϽ0.05).
Coronary Flow and Enzyme Release From Isolated Perfused Hearts
Coronary perfusion increased at 5 minutes of reperfusion in wt and tg hearts by 45% and 72%, respectively, over the preischemic control (reactive hyperemia) and declined within 20 minutes in both groups to values comparable to the preischemic control. Wt and tg hearts did not differ significantly in coronary perfusion.
The release of CK and LDH into the coronary effluate is an established marker of myocellular injury. Before ischemia, CK and LDH activities were very low and similar in wt and tg hearts ( Table 2 ). During reperfusion, the release of CK from wt hearts markedly increased to a maximum of 2.7Ϯ0.3 U/minϫg at 15 minutes of reperfusion (Figure 4) . In contrast, CK activity was markedly lower in the tg hearts, where the highest activity (0.4Ϯ0.2 U/minϫg) was found at 5 minutes of reperfusion. This was significantly less than in wt (PϽ0.05). Similar results were obtained for LDH activity (wt, 1.49Ϯ0.50 U/Lϫmin; tg, 0.36Ϯ0.33 U/Lϫmin at 15 minutes of reperfusion).
Effect of ␤-Adrenergic Receptor Inhibition in Isolated Perfused Hearts
EP 3 receptor overexpression may oppose the detrimental effects of catecholamines during ischemia. To examine the importance of ␤-adrenoceptor stimulation during ischemia and reperfusion, isolated perfused tg and wt hearts were also subjected to ischemia/reperfusion in the presence of a ␤ 1 -adrenergic antagonist (3 mol/L talinolol).
In wt hearts, talinolol remarkably delayed the onset of ischemic contracture (LVEDP) from 10 minutes in untreated hearts ( Figure  4 ) to 30 minutes ( Figure 5 ). The maximum LVEDP at 60 minutes of ischemia (24.0Ϯ8.3 versus 40.0Ϯ3.6 mm Hg) was also lowered, although this did not reach statistical significance (Pϭ0.06). Throughout ischemia and reperfusion, ␤-adrenergic blockade largely abolished the difference in ischemia-induced contracture (LVEDP) between wt and tg hearts.
The release of CK into the coronary effluate was also attenuated by the ␤-adrenergic antagonist. In wt hearts, talinolol reduced peak CK activity (15 minutes of reperfusion) from 
Discussion
This study shows that the overexpression of EP 3 receptors on cardiomyocytes protects from ischemia/reperfusion-induced myocardial injury. Although indirect evidence from our laboratory and others suggested the presence of EP 3 receptors in the heart 7,10 and ligand binding experiments indicated the presence of this receptor on cardiac sarcolemma, 14 it is unknown whether EP 3 receptors on cardiomyocytes mediate antiischemic effects. Clearly, noncardiomyocyte EP 3 receptors may attenuate ischemia-induced injury. For example, sympathetic nerve fibers express presynaptic inhibitory EP 3 receptors, 20 which may inhibit the deleterious ischemia-related increase in tissue levels of catecholamines. An inhibition of ischemia-induced overflow of noradrenaline from adrenergic nerve terminals has originally been shown by our laboratory for PGI 2 . 21 Moreover, sympathetic nerve activity is also under control of central EP 3 receptors, 22 which may be activated by systemic administration of EP 3 agonists. EP 3 receptors are also localized in vascular tissues, 23 where they may influence regional perfusion. Thus, it is unknown where the cardioprotective EP 3 receptors are located.
The present study was undertaken to resolve this uncertainty by cardiomyocyte-specific EP 3 overexpression. According to ligand binding studies, tg mice overexpressed the EP 3 subtype Ϸ40-fold at similar receptor affinity, with negligible expression in other tissues. EP 3 overexpression caused a moderate reduction of left ventricular performance in vivo, as shown by a slightly increased end-systolic volume and moderately reduced ejection fraction. This may be explained by the observed constitutive receptor activity, attenuating sympathoadrenergic drive at the level of adenylate cyclase. Nevertheless, this effect was moderate, because cardiac output and end-diastolic volumes remained unchanged in tg animals. Moreover, the baseline myocardial function of isolated perfused hearts was comparable in wt and tg hearts with respect to ⌬LVP and dP/dt. Because heart rate in the isolated preparation was kept constant by pacing, a comparable oxygen consumption in the wt and tg hearts may be assumed. Hence, EP 3 overexpression did not induce a negative inotropic effect that could have attenuated the severity of ischemia.
A conspicuous finding of this study was the impressive reduction in ischemic myocardial contracture in the tg hearts, a complication of prolonged myocardial ischemia also seen in clinical settings. 24 Ischemic contracture has been attributed to a rise in intracellular free calcium or a progressive loss of ATP at the myofibrils. 25, 26 It is noteworthy that some protective interventions such as ischemic preconditioning augment ischemia-induced contracture, 27, 28 whereas others such as activation of A 1 adenosine receptors or inhibition of L-type calcium channels reduce contracture. 29, 30 The antiischemic action of EP 3 overexpression became also evident during reperfusion, in which the release of CK and LDH into the coronary effluate was significantly reduced in the tg hearts to Ͻ25% of wt.
Coupling to G i is the primary signal transduction pathway of all EP 3 receptor subtypes. Thus, the observed reduction in ischemic contracture in EP 3 -overexpressing hearts may be explained by a functional antagonism of G i -coupled EP 3 receptors with cAMP-mediated Ca 2ϩ influx by counteracting the effect of the ischemia-induced overflow of endogenous catecholamines. 21 Indeed, ischemic myocardial contracture is attenuated by the experimental depletion of endogenous catecholamines and accelerated by ␤-adrenoceptor overexpression. 31, 32 Interestingly, the overexpressed EP 3 receptor is constitutively active, as shown by the attenuated forskolin-dependent cAMP formation in tg cardiocytes. This finding is expected, because earlier studies demonstrated constitutive activity of some EP 3 isoforms (EP 3␣ and EP 3␥ ). 33, 34 Constitutive activity of the transgenic EP 3 receptor is also suggested by attenuation of the inotropic effect of isoproterenol in isolated perfused tg hearts. This constitutive activity enabled us to study the antiischemic action of EP 3 receptors in the isolated heart preparation in the absence of an EP 3 agonist, which excluded any possible nonspecific or cardiomyocyte-independent drug effects.
The EP 3 agonist M&B 28.767 did not decrease cAMP in wt or tg cardiomyocytes. This can be explained by the observed constitutive activity of tg cardiomyocytes. In wt cells, it is likely that the expression of EP 3 receptors was too low to be detected in vitro by reduction of forskolin-stimulated cAMP. It is also possible that the wt EP 3 receptors are constitutively active or couple to G i -independent pathways. Thus, this study does not answer the question of whether the basal expression of wt EP 3 receptors is sufficiently high to protect cardiomyocytes from ischemic injury. Future work may clarify this issue by generating cardiomyocyte-specific EP 3 -knockout mice. It should be noted, however, that cardiac EP 3 receptor density increases during acute myocardial ischemia by Ϸ50%, probably by externalization from an intracellular compartment. 14 This may increase the efficacy of EP 3 -mediated inhibition of adenylate cyclase during ischemia. The experimental overexpression may simulate this pathophysiological response to ischemia in an augmented form.
Provided that a G i -mediated inhibition of cAMP-dependent pathways downstream of ␤-adrenergic receptors underlies the antiischemic effect of EP 3 overexpression, one would expect similar results from inhibition of adrenergic responses by different pharmacological means. For this reason, we subjected isolated hearts from wt and tg mice to the identical ischemia/reperfusion protocol in the presence a ␤ 1 -selective antagonist (talinolol). Indeed, ischemic contracture and CK release were also attenuated by ␤-adrenergic blockade in the wt hearts. Of note, the difference between wt and tg in both LVEDP and CK release was no more significant in presence of the ␤-adrenergic antagonist. This supports the hypothesis that G i -mediated inhibition of adenylate cyclase mediates the antiischemic effect in the EP 3 -overexpressing hearts.
Besides coupling to G i , additional mechanisms may certainly contribute to the antiischemic effects of EP 3 receptors. For example, ischemic contracture is linked to the Na ϩ /H ϩ exchanger (NHE-1). The intracellular acidosis during myocardial ischemia may activate the sarcolemmal NHE-1 with subsequent Na ϩ influx, cytosolic Ca 2ϩ overflow, and ischemic contracture. Because NHE-1 is negatively regulated by inhibitory G proteins (G i␣ ), 35 it is possible that it may also contribute to the inhibition of ischemic contracture by EP 3 overexpression. In addition, Zacharowski and coworkers 36 reported that the inhibition of mitochondrial K ATP channels by 5-hydroxydecanoic acid counteracts the cardioprotection by EP 3 receptor agonists, but the role of K ATP for prostaglandinmediated cardioprotection is still unclear. 37, 38 Finally, EP 3 receptors may also activate the PKC pathway. Some isoforms stimulate PLC␤ via G ␤␥ or G ␣q subunits. 9, 39 Although detailed identification of the signaling pathway downstream of the overexpressed EP 3 receptor was not an aim of this study, we have addressed PKC signaling by determining PKC-dependent substrate phosphorylation. As a result, there was no detectable increase in PKC-dependent phosphorylation, which would argue against a contribution of PKC. Nevertheless, an activation of this pathway may have been below the threshold for detection. Therefore, the possibility of PKC involvement cannot be excluded and should be addressed in future experiments.
In summary, this study shows that EP 3 receptors, constitutively overexpressed in a cardiomyocyte-specific manner, are functionally active and couple to PTX-sensitive inhibitory G proteins (G i ), eventually resulting in an inhibition of adenylate cyclase and subsequent decrease in cardiomyocyte cAMP formation. EP 3 overexpression induced a moderate reduction in myocardial contractile activity in vivo (MRI), which was not apparent during isolated perfusion. EP 3 receptor overexpression remarkably reduced ischemia-induced myocardial injury in isolated hearts, as shown by a delayed onset and attenuation of ischemic contracture, as well as a reduced release of myocellular enzymes during reperfusion. The reduction in ischemia-induced injury by EP 3 overexpression suggests a cardioprotective role of this receptor subtype when expressed on cardiomyocytes.
